Mobile

A long term extension trial of BI 655066/ABBV-066 (risankizumab) in patients with moderately to severely active Crohn's disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-001834-15

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate long-term safety of BI 655066/ABBV-066 (risankizumab), in patients with moderately to severely active Crohn`s disease, who showed a clinical response or remission on previous treatment with BI 655066/ABBV-066 (risankizumab) and are now receiving long-term treatment.

Critère d'inclusion

  • Crohn’s Disease

Liens